Karen Pendergrass, Standards Team

By directly targeting microbial dysbiosis, hormonal imbalances, and inflammation, metformin not only validates the clinical relevance of the endometriosis microbiome signature but also positions itself as an effective therapeutic option for the condition.

Hyperglycemia weakens placental immunity in DM, increasing bacterial invasiveness. Metformin reduces bacterial counts of E. coli and S. agalactiae, providing protective benefits beyond insulin. Cytokine tolerization under hyperglycemia highlights the need for enhanced therapeutic interventions.

Pueraria Flower Extract (FE) addresses microbial imbalances and inflammation in endometriosis, validating its role as a microbiome-targeted therapy.

Pueraria thomsonii flower extract reduces visceral fat and MI without sexual dimorphism, offering a safe intervention for obesity management.

This study demonstrates the potential of ¹MR metabolomics to diagnose endometriosis non-invasively by identifying metabolic biomarkers and disrupted pathways. Quadratic Discriminant Analysis outperformed Artificial Neural Networks in diagnostic accuracy.

This study used 1H-MR metabonomics to identify serum biomarkers for early endometriosis diagnosis. Elevated lactate, alanine, and reduced glucose levels highlight metabolic disruptions, offering a minimally invasive diagnostic tool.

This study highlights metabolic alterations in endometrial tissue and serum of minimal and mild endometriosis patients, identifying amino acid biomarkers with diagnostic potential. A combined serum panel demonstrated 100% sensitivity and 83% specificity for Stage I diagnosis, offering a promising step toward non-invasive early detection of endometriosis.

This study links cervical microbiome diversity with endometriosis severity. Findings reveal microbial imbalances, particularly in advanced stages, correlate with pain, infertility, and inflammatory pathways. The cervical microbiome may serve as a diagnostic and therapeutic target for improving outcomes in endometriosis, highlighting its role in reproductive health and disease progression.

This review highlights the bidirectional relationship between endometriosis and the microbiome, showcasing dysbiosis as a key factor in inflammation and estrogen metabolism. Emerging microbiome-targeted therapies hold promise for diagnosis and treatment.

This review highlights the gut and genital microbiome’s roles in estrogen-driven conditions like endometriosis, infertility, and PP, emphasizing dysbiosis’ impact on inflammation and estrogen metabolism.